MedCity Influencers, Health Tech There are resources medical institutions can draw on to relieve some of the burden from overworked, stressed-out physicians, nurses and staff – and many of them come in the form of technological advancements that may transform how we offer care in the years to come. https://medcitynews.com/author/aphadnis
James K. Min James K. Min, MD, FACC is the founder and CEO of Cleerly, a mission-driven healthcare company whose digital care pathway supports physicians and patients by reducing risk of heart attacks. Previously, Min served as a full professor of Radiology and Medicine (Cardiology) at the Weill Cornell Medical College and Director of the …
It’s a story of new year, new antibody-drug conjugate (ADC) technology at Genmab. Having previously partnered with ADC Therapeutics and Seagen, Genmab has now identified Synaffix as a good fit for its…
There are resources medical institutions can draw on to relieve some of the burden from overworked, stressed-out physicians, nurses and staff – and many of them come in the form of technological…
Regence is partnering with Strive Health to deliver comprehensive kidney care to 16,000 Regence Medicare Advantage and commercially insured plan members in several Western states. Our Sites © 2022 Breaking Media, Inc. All rights reserved. Registration or use of this site constitutes acceptance of our Terms of Service and Privacy Policy. Privacy Center | Do …
To improve heart attack prevention, there is an urgent unmet need to modernize our approach from late-stage symptom-driven care to direct disease-based care, a care paradigm that addresses heart…
In order to benefit from the Virtual1Care trend, pharma and medtech companies must ensure that their digital health tools, wrapped around a drug or device, comply with evolving regulations.
Regence is partnering with Strive Health to deliver comprehensive kidney care to 16,000 Regence Medicare Advantage and commercially insured plan members in several Western states.
Avrobio is stopping enrollment in a clinical trial for its Fabry disease program after new results showed variability in how the gene therapy was taken up by patients. No safety problems were…
Health analytics firm Aetion has acquired Replica Analytics, a company that specializes in synthetic data. Aetion said Replica will enable it to analyze previously inaccessible data while maintaining…
